NovaBridge Biosciences (NBP)
Develops antibody drugs to treat cancer and eye diseases in clinical trials.
$1.73-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-34.0%
The outlook
NBP is trading near its 52-week lows and below its key moving averages, reflecting weak near-term momentum. Analyst coverage leans heavily bullish with an average price target roughly 362% above the current price, though the overall sentiment score remains bearish at 21/100. The wide gap between analyst targets and current price suggests significant disagreement in the market's view of the company's prospects.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Price targetAvg target +362% vs current price
Analyst price target
~12-month · 3 analysts$8.00average target+362.4% vs now
Now $1.73
Low $7.00High $9.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$200.1M
52-wk high
$6.79
52-wk low
$1.46
50-day avg
$1.75
200-day avg
$3.13
Trailing P/E
—